NCT04065555 - Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

June 20, 2022

Study Completion Date

July 20, 2022

Conditions

Head and Neck Cancer

Interventions

DRUG

TAK-981

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Cetuximab

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Avelumab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

TAK-981 + Cetuximab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

TAK-981 + Avelumab

Intratumoral microdose injection by the CIVO device.

Trial Locations (6)

Northwell Health (Lenox Hill), New York

Northwell Health (Monter Cancer Center), North New Hyde Park

University of Michigan, Ann Arbor

Oregon Health & Science University (OHSU), Portland

Portland VA, Portland

University of Washington, Seattle